Literature DB >> 21594797

Biochemical and biophysical approaches to probe CFTR structure.

André Schmidt1, Juan L Mendoza, Philip J Thomas.   

Abstract

The cystic fibrosis transmembrane regulator (CFTR) is a multi-domain integral membrane protein central to epithelial fluid secretion (see Chapter 21). Its activity is defective in the recessive genetic disease cystic fibrosis (CF). The most common CF-causing mutation is F508del in the first nucleotide binding domain (NBD1) of CFTR. This mutation is found on at least one allele of more than 90% of all CF patients. It is known to interfere with the trafficking/maturation of CFTR through the secretory pathway, leading to a loss-of-function at the plasma membrane. Notably, correction of the trafficking defect by addition of intragenic second-site suppressor mutations, or the alteration of bulk solvent conditions, such as by reducing the temperature or adding osmolytes, leads to appearance of functional channels at the membrane--thus, the rescued F508del-CFTR retains measurable function. High-resolution structural models of NBD1 from X-ray crystallographic data indicate that F508 is exposed on the surface of the domain in a position predicted by homologous ABC transporter structures to lie at the interface with the intracellular loops (ICLs) connecting the transmembrane spans. Determining the relative impact of the F508del mutation directly on NBD1 folding or on steps of domain assembly or both domain folding and assembly requires methods for evaluating the structure and stability of the isolated domain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594797      PMCID: PMC3266684          DOI: 10.1007/978-1-61779-117-8_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  48 in total

1.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

2.  A bacterial system for investigating transport effects of cystic fibrosis--associated mutations.

Authors:  A L Gibson; L M Wagner; F S Collins; D L Oxender
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

3.  Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast.

Authors:  J L Teem; H A Berger; L S Ostedgaard; D P Rich; L C Tsui; M J Welsh
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

4.  Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.

Authors:  Shane Atwell; Christie G Brouillette; Kris Conners; Spencer Emtage; Tarun Gheyi; William B Guggino; Jorg Hendle; John F Hunt; Hal A Lewis; Frances Lu; Irina I Protasevich; Logan A Rodgers; Rich Romero; Stephen R Wasserman; Patricia C Weber; Diana Wetmore; Feiyu F Zhang; Xun Zhao
Journal:  Protein Eng Des Sel       Date:  2010-02-11       Impact factor: 1.650

5.  Degradation of CFTR by the ubiquitin-proteasome pathway.

Authors:  C L Ward; S Omura; R R Kopito
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

6.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

7.  The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein.

Authors:  Y H Ko; P J Thomas; M R Delannoy; P L Pedersen
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

8.  The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment.

Authors:  Y Yang; S Janich; J A Cohn; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

9.  Mild course of cystic fibrosis associated with heterozygosity for infrequent mutations in the first nucleotide-binding fold of CFTR.

Authors:  T Dörk; U Wulbrand; G Steinkamp; B Tümmler
Journal:  Acta Paediatr       Date:  1992-01       Impact factor: 2.299

10.  Recombinant synthesis, purification, and nucleotide binding characteristics of the first nucleotide binding domain of the cystic fibrosis gene product.

Authors:  J Hartman; Z Huang; T A Rado; S Peng; T Jilling; D D Muccio; E J Sorscher
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

View more
  3 in total

1.  Membrane protein stability can be compromised by detergent interactions with the extramembranous soluble domains.

Authors:  Zhengrong Yang; Chi Wang; Qingxian Zhou; Jianli An; Ellen Hildebrandt; Luba A Aleksandrov; John C Kappes; Lawrence J DeLucas; John R Riordan; Ina L Urbatsch; John F Hunt; Christie G Brouillette
Journal:  Protein Sci       Date:  2014-05-03       Impact factor: 6.725

2.  Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.

Authors:  Julien Colas; Grazyna Faure; Emilie Saussereau; Stéphanie Trudel; Wael M Rabeh; Sara Bitam; Ida Chiara Guerrera; Janine Fritsch; Isabelle Sermet-Gaudelus; Noëlie Davezac; Franck Brouillard; Gergely L Lukacs; Harald Herrmann; Mario Ollero; Aleksander Edelman
Journal:  Hum Mol Genet       Date:  2011-10-28       Impact factor: 6.150

3.  A chaperone trap contributes to the onset of cystic fibrosis.

Authors:  Judith A Coppinger; Darren M Hutt; Abbas Razvi; Atanas V Koulov; Sandra Pankow; John R Yates; William E Balch
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.